

## Pharmacy Medical Necessity Guidelines: Glucagon Products

Effective: January 1, 2021

Prior Authorization Required	√	Type of Review – Care Management	
Not Covered		Type of Review – Clinical Review	√
Pharmacy (RX) or Medical (MED) Benefit	RX	Department to Review	RXUM
<p>These pharmacy medical necessity guidelines apply to the following:</p> <p><b>Commercial Products</b></p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Tufts Health Plan Commercial products – large group plans</li> <li><input type="checkbox"/> Tufts Health Plan Commercial products – small group and individual plans</li> <li><input type="checkbox"/> Tufts Health Freedom Plan products – large group plans</li> <li><input type="checkbox"/> Tufts Health Freedom Plan products – small group plans</li> <li>• CareLink<sup>SM</sup> – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization</li> </ul> <p><b>Tufts Health Public Plans Products</b></p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product)</li> <li><input checked="" type="checkbox"/> Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans</li> <li><input type="checkbox"/> Tufts Health RITogether – A Rhode Island Medicaid Plan</li> </ul>		<p><b>Fax Numbers:</b> RXUM: 617.673.0988</p>	

**Note:** This guideline does not apply to Medicare Members (includes dual eligible Members).

### OVERVIEW

Gvoke (glucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes 2 years of age and older.

Baqsimi (nasal powder) is indicated for the treatment of severe hypoglycemia in patients with diabetes who are 4 years of age and older. It is recommended for intranasal use only.

Baqsimi is covered without Prior Authorization and is the preferred glucagon product for Tufts Health Together.

### COVERAGE GUIDELINES

The plan may authorize coverage for Gvoke (glucagon) injection when the following criteria are met and no limitations apply:

1. The Member has a diagnosis of diabetes mellitus
- AND**
2. One of the following are met:
    - a. The Member is at least 2 years of age and less than 4 years of age

**OR**

    - b. The Member had an inadequate response, intolerance, or contraindication to Baqsimi (glucagon nasal powder)

### LIMITATIONS

1. Members who are at least 2 years of age and less than 4 years of age will be approved for two years.

### CODES

None

### REFERENCES

1. Baqsimi (glucagon) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; July 2019.
2. Gvoke (glucagon) [prescribing information]. Costa Mesa, CA: Xeris Pharmaceuticals, Inc; September 2019.

### APPROVAL HISTORY

November 24, 2020: Reviewed by Pharmacy & Therapeutics Committee.

Subsequent endorsement date(s) and changes made:

- 1.

### BACKGROUND, PRODUCT AND DISCLAIMER INFORMATION

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage

decisions are made. The plan makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Pharmacy Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.